Objective: To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets. Methods: Between 1996 and 2004, representative serum banks were established in 17 countries by collecting residual sera or community sampling. Serum banks were tested in each country and assay results were standardized. With a questionnaire, we collected information on current and past rubella vaccination programmes in each country. The percentage of seronegative (< 4 IU/ml) children (2-14 years of age) was used to evaluate rubella susceptibility, and countries were classified by seronegativity as group I (< 5%), group II (5-10%) or group III (> 10%). The proportion of women of childbearing age without rubella protection (≤ 10 IU/ml) was calculated and compared with WHO targets of < 5%.
Introduction
Rubella is a mild viral disease of little clinical significance in children and adult males. However, rubella infection in pregnancy is of major public health importance due to the teratogenic effects that can result from congenital rubella infection, which can lead to miscarriage, fetal death or birth of an infant with congenital rubella syndrome. 1 Since the licensing of the first rubella vaccine in the late 1960s, the aim of rubella vaccination programmes has been the prevention of congenital rubella syndrome as a complication of rubella infection during pregnancy. Many countries first selectively vaccinated adolescent females, thus creating a cohort of immunized women of childbearing age. 2 Since the introduction of a combined measles-mumps-rubella (MMR) vaccine, many countries have introduced childhood immunization programmes for rubella. 3 Such programmes are established in most European countries, 4 thus preventing the transmission of rubella and providing indirect protection to pregnant women.
If childhood rubella vaccination programmes do not attain the herd immunity threshold of about 80%, then a paradoxical increase in congenital rubella syndrome can occur due to a decreased circulation of the virus and an accumulation of susceptible adult females. 5 This increase in the syndrome in the presence of a suboptimum vaccination programmes has been reported in Europe 6,7 and underpinned the earlier WHO European recommendation of less than 5% 16 The comparison of rubella seroepidemiology in the participant countries of ESEN2 will inform progress towards international disease-control targets and allow countries to develop evidence-based and cost-effective interventions to achieve these international goals.
Methods

National serum-bank collection
Seventeen countries (Australia and 16 in WHO Europe Region) tested for rubella IgG antibody in sera specimens collected between 1996 and 2004 (Table 1, available at: http://www.who.int/bulletin/volumes/86/2/07-042010/en/index.html). The sera were obtained either by residual sera collected during routine laboratory testing (11 of 17), by population-based random sampling (five of 17), or a combination of these two methods (one of 17). Ethical approval was sought from the appropriate national authorities for all collections.
Sera were collected from all age groups, were evenly distributed between males and females and were geographically representative of each country ( Vaccine programme, coverage and rubella incidence
In March 2002, all ESEN national representatives were sent a standardized questionnaire that collected current and historical information regarding both the rubella vaccination programmes (age groups targeted, vaccines used and vaccine coverage) and the incidence of reported disease.
This information was updated in 2006 with data from the WHO Health for All databases.
Standardization and reference assay
The methodology and results of the standardization of the rubella assays have been described In two countries (Israel and Sweden), the national serum banks had been tested over a year before the distribution of the reference panel. A back-standardization, described elsewhere, 18 was done in those countries to standardize their results to common project units.
Local titres were converted to standard titres by regressing the results of the panel testing of the national centre against those of the reference centre and thus obtaining standardization equations. 17, 18 Each national serum bank was tested with the same validated assay used for the reference panel. The country-specific standardization equations were used to convert the local quantitative results into standardized reference titres.
Data analysis
The following cut-offs were applied to standardized antibody titres: < 4 IU/ml were seronegative samples, 4-7 IU/ml were equivocal and > 7IU/ml were seropositive. Equivocal samples were included with seropositives only if stated. Among women of childbearing age, protective immunity was defined as a rubella antibody titre > 10 IU/ml.
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Countries with childhood vaccination programmes were allocated into one of three groups according to the percentage seronegative children (2-14 years of age):
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• Group I (< 5% seronegativity)
• Group II (5-10% seronegativity)
• Group III (> 10% seronegativity).
Results
Rubella vaccination programmes
Of the 17 countries, only Romania had no rubella vaccination programme at the time of the serum bank collection in 2002 ( http://www.who.int/bulletin/volumes/86/2/07-042010/en/index.html).
The remaining 16 countries all routinely immunized all children with a two-dose MMR vaccine schedule ( Table 2 ). The first dose of the MMR vaccine was given between ages 13 and 20 months, but the recommended age for the second MMR dose varied from 21 months in the Czech
Republic to 12 years in Bulgaria, Malta and Sweden (Table 2) .
Eleven countries initially introduced a programme of selective vaccination of adolescent females (Table 2) . Five countries (Cyprus, the Czech Republic, Lithuania, Slovenia and Sweden)
implemented rubella vaccination of children as a two-dose regime. The remaining 11 countries first implemented rubella vaccination as a single infant dose and a two-dose regimen was introduced between 3 years (Malta) and 9 years (Belgium, Bulgaria and Latvia) later (Table 2) .
Antenatal screening for rubella susceptibility was done in six of the 17 countries (35%).
Prevaccination serology
In Romania, before the introduction of rubella vaccination, the seroprevalence of rubella increased with age ( Five countries were defined as group I (less than 5% of children were seronegative for rubella):
Australia (4.6%), the Czech Republic (0.9%), Hungary (2.2%), Slovakia (2.9%) and Slovenia (3.7%; Table 3 ). In all countries, the average reported infant vaccine coverage was at least 93%, while the average incidence of rubella disease was less than one per 100 000 population except in Australia (1.3 per 100 000) and the Czech Republic (11.3 per 100 000, Table 2 ).
In Hungary, Slovakia and Slovenia this level of control (< 5% seronegativity) was maintained in young adults (Table 3 ), but not in the Czech Republic and Australia, due to high seronegativity among adult males (11.6% and 16% respectively, Table 3 ) who had not been targeted by any rubella vaccination campaign. In Australia, The Czech Republic, Slovakia and Slovenia less than 5% of women of childbearing age did not have protective immunity (Table 4 ).
In the Czech Republic and Hungary, the proportion of women of childbearing age without protective immunity reached a maximum in 30-39-year-old women (7.0% and 10.6%
respectively) who would not have been targeted by any rubella vaccination programme.
Group II countries
Seven countries were defined as group II (5-10% seronegativity in children): Cyprus (8.7%), Israel (6.8%), Latvia (8.7%), Lithuania (5.6%), Luxembourg (5.2%), Malta (6.8%) and Sweden (8.8%; Table 3 ). In Sweden, protective immunity among women of childbearing age was less than 5% (Table 4) , but samples were only collected from selected age groups (Table 1) . Two countries (Luxembourg and Sweden) have been included in this group although direct comparisons with other countries are difficult as samples were collected from restricted age groups (Table 1) (Table 2 ).
In two countries (Cyprus and Malta), the percentage of seronegative people declined with increasing age, in Cyprus from 13.3% in 2-4 year olds to 6.5% in 10-14 year olds and in Malta from 9.6% to 6.2% (Table 3) . This is probably due to the administration of a second MMR dose for which no coverage data were available.
In Israel, Latvia and Lithuania, the highest levels of seronegativity were among children in the oldest age group (10-14 years; Table 3 ). In Lithuania, although older age groups had been targeted with one dose of rubella vaccine introduced for 12year olds between 1992 and 2001, coverage was often low (Annex 1) and seronegativity was higher in older children (8.1% in 10-14year olds) than in younger children (< 5%; Table 3 ). In Israel and Latvia, as boys older than 11 years old would not have been targeted by a rubella vaccination programme, the higher levels of seronegativity among older children was due to gender differences with higher seronegativity among older males than females ( Fig. 1 and Fig. 2 ).
In Luxembourg, seronegativity was just over 5% in children (5.2%). A higher percentage of seronegativity was observed in 15-19 year olds (11%; data not shown) as those older than 15 years had not been targeted by any rubella vaccination programme, 20 and 11% of females in this age group were without protective immunity against rubella (Table 4 ). In Sweden, seronegativity increased from 1% in 2year olds to a maximum of 16.2% in 10year olds and declined to 1% in 14year olds after the second MMR dose at 12 years of age (Annex 1).
Group III countries
Four countries were defined as group III with greater than 10% seronegativity in children:
Belgium (12.8%), Bulgaria (28.4%), England and Wales (15.7%), and Ireland (12.9%; Table 3 ).
The reported average infant vaccine coverage for the 5 years from 1999-2003 was greater than 90% in Bulgaria (93%) and 85% or less in the remaining three countries (1999 data for Belgium; Table 2 ). In Bulgaria, the average incidence of notified rubella disease for the same period was 86.8 per 100 000, while it was less than two per 100 000 in the other three countries (data 2001-2003 for Belgium; Table 2 ).
The percentage of seronegative people within the three childhood age groups ranged from 8.5% of 10-14year olds in Belgium to 28.9% of 2-4year olds in Bulgaria. Over 5% of women of childbearing age were without antibody levels needed for protective immunity (i.e. > 10 IU/ml), ranging from 6.2% in England and Wales to 13.4% in Belgium, with the highest percentages among younger women of childbearing age, reaching nearly 20% (17.5%) of 15-19-year-old
Belgian females (Table 4 ).
Discussion
We report on an international study comparing the seroepidemiology of rubella in The target set by the WHO European strategic plan for the prevention of CRI is to reduce the incidence of congenital rubella syndrome to less than one case per 100 000 live births annually and of rubella to less than one per 100 000 population by 2010. 10 Nine of the 17 countries had achieved the target of rubella incidence. Many countries reported low rubella vaccine coverage of infants, although such estimates did not account for those vaccinated in either a second dose or catch-up campaigns in older age groups. Nonetheless, some countries have reported improved MMR vaccine coverage since the time of the serosurveys.
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In the absence of age-specific susceptibility targets for rubella elimination, as there are for measles, we have used the percentage of seronegative children to categorize a country's susceptibility to rubella outbreaks. We have based these groups on mathematical models which demonstrated that in low-transmission and intermediate-transmission countries the proportion of infants needed to be immunized to eliminate the risk of infection in women of childbearing age should be greater than 80%, but in high transmission countries this needed to be greater than 90%. 22 Wide variations in the herd immunity thresholds for rubella have been estimated in different European countries, although these thresholds are lower than for measles.
23
In Romania, the absence of any control programme for rubella resulted in a rubella epidemic with subsequent increase in congenital rubella syndrome. 24 In the remaining 15 countries, childhood immunity was above putative thresholds to block endemic transmission.
Seronegativity among children was greater than 10% in the four group III countries (Belgium, Bulgaria, England and Wales, and Ireland), at which level modelling studies have estimated that smaller epidemics could occur. 24 Efforts to improve rubella immunity among children are needed to prevent the occurrence of such outbreaks in these countries and ensure that the indirect protection offered to pregnant women is maintained. However, one assumes that vaccine coverage is uniform across geographical and social groups, and this is not always the case has observed by the recent outbreak of rubella in the Netherlands leading to cases of congenital rubella syndrome.
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In previous WHO strategies, targets of less than 5% rubella susceptibility among women of childbearing age have been set. 8 Only Australia and four European countries (the Czech Republic, Slovakia, Slovenia and Sweden) had achieved a protective immunity of less than 5% In situations where there is no circulation of wild virus due to effective rubella vaccination policies, antibody titres wane 15 years after vaccination; 27 although, of the three components of the MMR vaccine, the rubella vaccine-induced antibody response has been reported as the strongest. 28 This emphasizes the importance of ensuring that a two-dose rubella immunization is routinely given. 29 The seroprofiles of several countries illustrate the possible boosting of the rubella antibody response upon administration of subsequent rubella doses (e.g. Sweden).
Nonetheless, the timing of the second rubella dose is critical to ensure that rubella immunity is maintained in women of childbearing age.
In some countries, we have observed a failure to ensure adequate protection at the time of changes in rubella vaccination programmes, although these often tend to be short-lived and of limited public-health importance. However, in several countries there are large cohorts of susceptible males who were not targeted by selective vaccination and too old for the childhood vaccination programme and these can act as foci for rubella epidemics. 30, 31 This underlines the importance of ensuring proper levels of protection in males and, despite evident difficulties, that they are included in any catch-up vaccination campaigns.
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Two-dose childhood vaccination programmes for rubella have now been implemented in all countries that participated. However, international disease-control targets for rubella could be missed in many countries unless these programmes are strengthened by improved routine coverage of children and, where appropriate, catch-up campaigns in older age groups.
Furthermore, rubella immunization programmes should be strengthened in conjunction with the 
